Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 10 |
| List of Tables | 9 | 3 |
| List of Figures | 12 | 4 |
| Introduction | 16 | 1 |
| GlobalData Report Guidance | 16 | 1 |
| Overview of the Pharmaceutical and Medical Device Markets | 17 | 43 |
| Pharmaceutical Market | 17 | 1 |
| Market Overview | 17 | 3 |
| Pharmaceutical Exports and Imports | 20 | 1 |
| Supply Channels | 21 | 1 |
| Market Segments | 22 | 1 |
| Generic Drugs | 22 | 1 |
| Biologics/Biosimilars | 22 | 1 |
| Over-the-Counter Drugs | 23 | 1 |
| Major Disease Areas | 23 | 1 |
| Antibacterials for Systemic Use | 23 | 1 |
| Lipid-Modifying Agents | 24 | 1 |
| Anti-diabetics | 24 | 1 |
| Agents Acting on Renin-Angiotensin System | 24 | 1 |
| Antineoplastic Agents | 24 | 1 |
| Major Companies | 25 | 1 |
| Pharmaniaga | 25 | 1 |
| Overview | 25 | 1 |
| Product Portfolio | 26 | 1 |
| Research and Development | 27 | 1 |
| SWOT Analysis | 27 | 4 |
| Chemical Company of Malaysia | 31 | 1 |
| Overview | 31 | 1 |
| Product Portfolio | 32 | 1 |
| Research and Development | 33 | 1 |
| SWOT Analysis | 33 | 4 |
| Yung Shin Pharmaceuticals | 37 | 1 |
| Company Overview | 37 | 1 |
| Product Portfolio | 38 | 2 |
| Research and Development | 40 | 1 |
| SWOT Analysis | 40 | 3 |
| Hovid | 43 | 1 |
| Overview | 43 | 1 |
| Product Portfolio | 44 | 1 |
| Research and Development | 45 | 1 |
| SWOT Analysis | 45 | 4 |
| Kotra Pharma | 49 | 1 |
| Overview | 49 | 1 |
| Product Portfolio | 50 | 1 |
| SWOT Analysis | 51 | 3 |
| Medical Device Market | 54 | 3 |
| Market Drivers and Barriers | 57 | 1 |
| Drivers | 57 | 1 |
| Barriers | 58 | 2 |
| Market Access | 60 | 31 |
| Reimbursement and Payer Landscape | 60 | 1 |
| Overview of Healthcare System | 60 | 1 |
| Reimbursement Process | 61 | 1 |
| Overview of Insurance Providers | 62 | 1 |
| Public Insurance | 62 | 1 |
| Social Security Organisation | 62 | 1 |
| Employees Provident Fund | 63 | 1 |
| Private Insurance | 64 | 1 |
| Patient Share in Healthcare Spending | 65 | 1 |
| Price Trends in the Healthcare Sector | 66 | 1 |
| Pricing Policies | 67 | 1 |
| Regulatory Landscape | 67 | 1 |
| Overview of Regulatory Agencies | 67 | 1 |
| Market Authorization Procedure for Pharmaceutical Products | 68 | 2 |
| Registration Process for Generic Products | 70 | 1 |
| Registration Process for Biological/Biotechnological Products | 71 | 2 |
| Market Authorization Procedure for Medical Devices | 73 | 1 |
| Licensing Process for Pharmaceutical and Medical Device Manufacturing | 74 | 1 |
| Licensing Process for Pharmaceutical Manufacturing | 74 | 1 |
| Licensing Process for Medical Device Manufacturing | 75 | 1 |
| Licensing Process for Pharmaceutical Exports and Imports | 76 | 1 |
| Halal Certification Process | 77 | 1 |
| Intellectual Property Rights | 78 | 1 |
| Patents | 78 | 3 |
| Trademarks | 81 | 1 |
| Clinical Trial Regulations | 82 | 2 |
| Import License for Clinical Trials for a New Drug | 84 | 2 |
| Pharmaceutical Advertising Regulations | 86 | 1 |
| Pharmaceutical Advertisement Approval Process | 87 | 1 |
| Pharmacy Regulations | 88 | 1 |
| Labeling and Packaging Regulations | 89 | 2 |
| Country Analysis | 91 | 60 |
| Political Environment | 91 | 1 |
| Political Structure | 91 | 2 |
| Analysis of the Current Political Environment | 93 | 1 |
| Healthcare Policy Initiatives | 94 | 2 |
| Economic Landscape | 96 | 2 |
| Economic Indicators | 98 | 1 |
| Gross Domestic Product | 98 | 1 |
| GDP Per Capita | 98 | 1 |
| 9T Annual Change in 9TGross Domestic Product | 99 | 3 |
| Gross National Income | 102 | 1 |
| Inflation | 103 | 1 |
| Consumer Price Index | 103 | 2 |
| Annual Change in Consumer Price | 105 | 1 |
| Currency Exchange Rate | 106 | 1 |
| Foreign Direct Investment | 107 | 1 |
| Foreign Exchange Reserves | 108 | 1 |
| Trade Balance | 109 | 1 |
| Imports of Goods and Services | 109 | 1 |
| Exports of Goods and Services | 110 | 1 |
| General Government Structural Balance | 111 | 1 |
| General Government Gross Debt | 112 | 2 |
| Major Industries | 114 | 1 |
| Demographics | 115 | 1 |
| Population | 115 | 2 |
| Urban0T 0TRural Share | 117 | 2 |
| Distribution by Age Groups | 119 | 2 |
| Birth Rate | 121 | 1 |
| Mortality | 122 | 1 |
| Causes of Mortality | 123 | 1 |
| Health Status by Gender and Age | 124 | 4 |
| Gender Ratio | 128 | 1 |
| Life Expectancy | 129 | 1 |
| Education and Literacy | 130 | 1 |
| Employment | 131 | 1 |
| Disease Burden | 132 | 1 |
| Disability-Adjusted Life Years | 133 | 2 |
| Healthcare Infrastructure | 135 | 1 |
| Healthcare Facilities | 135 | 1 |
| Public and Private Hospitals | 136 | 1 |
| Diagnostic Facilities | 137 | 1 |
| Healthcare Parameters | 138 | 1 |
| Hospital-Bed-to-Population Ratio | 138 | 1 |
| Doctor-to-Population Ratio | 139 | 1 |
| Environmental Health | 140 | 1 |
| Air Pollution | 140 | 2 |
| Healthcare Personnel | 142 | 1 |
| Nurses-to-Population Ratio | 142 | 1 |
| Dentists-to-Population Ratio | 143 | 1 |
| Pharmacists-to-Population Ratio | 144 | 1 |
| Healthcare Expenditure | 145 | 1 |
| Overview | 145 | 1 |
| Major Components of Healthcare Spending | 146 | 1 |
| Public and Private Sector Share | 147 | 1 |
| Spending in Healthcare R&D | 148 | 1 |
| Trade Associations | 149 | 1 |
| Pharmaceutical Association of Malaysia | 149 | 1 |
| Malaysian Organization of Pharmaceutical Industries | 149 | 1 |
| Association of Private Hospital Malaysia | 149 | 1 |
| Association of Malaysian Medical Industries | 149 | 1 |
| Trade Fairs | 150 | 1 |
| Opportunities and Challenges | 151 | 2 |
| Opportunities | 151 | 1 |
| Challenges | 151 | 2 |
| Appendix | 153 | 15 |
| Abbreviations | 153 | 4 |
| Bibliography | 157 | 7 |
| Research Methodology | 164 | 3 |
| Coverage | 165 | 1 |
| Secondary Research | 165 | 1 |
| Forecasts | 166 | 1 |
| Expert Panel | 166 | 1 |
| Disclaimer | 166 | 2 |